RT Journal Article
SR Electronic
T1 Safety and Effectiveness of Ixazomib Dose-escalating Strategy in Ixazomib-Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 2821
OP 2828
DO 10.21873/invivo.12108
VO 34
IS 5
A1 OHASHI, YASUKATA
A1 YATABE, MEGUMI
A1 NIIJIMA, DAISUKE
A1 TANI, KENTARO
A1 OGAWA, CHIAKI
A1 YACHI, YUTAKA
A1 KAGOO, TOSHIYA
A1 BOKU, SAIGEN
A1 UENO, HIRONORI
A1 YANO, TAKAHIRO
A1 HIGAI, KOJI
A1 YOKOYAMA, AKIHIRO
YR 2020
UL http://iv.iiarjournals.org/content/34/5/2821.abstract
AB Background/Aim: Gastrointestinal toxicity is common in patients receiving common therapy of ixazomib with lenalidomide and low-dose dexamethasone (IRd) for relapsed/refractory multiple myeloma. Here, we investigated the safety and effectiveness of ixazomib dosing schedules. Patients and Methods: We retrospectively evaluated 17 consecutive patients treated with IRd (10 patients on ixazomib dose-escalation strategy (2.3 mg starting dose); seven patients on standard dose). Results: The incidence of grade 3 or more haematological and grade 2 or more non-haematological adverse events was lower in the dose-escalation group than in the standard-dose group, and only that of diarrhoea was significantly lower. The median time to treatment interruption was significantly longer in the dose-escalation group than in the standard-dose group. There was no significant difference in the overall response rate (20% vs. 43%) and disease control rate (70% vs. 86%). Conclusion: A dose-escalation strategy to optimise ixazomib dosing may reduce treatment interruption due to adverse events without compromising its antitumor activity.